Research at The University of Texas MD Anderson Cancer Center identified DPY30 as a key epigenetic regulator that maintains genomic stability during replication stress in pancreatic tumors, pointing to a potential target to improve immunotherapy responsiveness. The work links DPY30 activity to tumor survival under DNA replication stress. In parallel oncology translational efforts, Dynamic42 and EPO announced a collaboration to bring organ-on-chip models into earlier glioblastoma preclinical decision-making, targeting differences in human versus non-human blood-brain barrier biology that contribute to poor brain-drug translation. Together, the updates reflect a continued focus on identifying actionable molecular dependencies and improving preclinical model fidelity—two areas that directly impact the probability of clinical success for late-stage oncology programs.